Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Tilio M, Gambini V, Wang J, Garulli C, Kalogris C, Andreani C, Bartolacci C, Elexpuru Zabaleta M, Pietrella L, Hysi A, Iezzi M, Belletti B, Orlando F, Provinciali M, Galeazzi R, Marchini C, Amici A.
Tilio M, et al. Among authors: gambini v.
Cancer Lett. 2016 Oct 10;381(1):76-84. doi: 10.1016/j.canlet.2016.07.028. Epub 2016 Jul 27.
Cancer Lett. 2016.
PMID: 27475932